Compare · NVO vs UPB
NVO vs UPB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Upstream Bio Inc. (UPB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and UPB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 940.9x UPB ($184.6M).
- NVO has hit the wire 4 times in the past 4 weeks while UPB has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 10 for UPB).
- Company
- Novo Nordisk A/S
- Upstream Bio Inc.
- Price
- -
- -
- Market cap
- $173.66B
- $184.6M
- 1M return
- -
- -48.45%
- 1Y return
- -
- -86.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest UPB
- General Counsel Ambrose Allison sold $2,663 worth of shares (485 units at $5.49), decreasing direct ownership by 3% to 15,563 units (SEC Form 4) to satisfy withholding tax
- CFO and COO Gray Michael sold $4,683 worth of shares (853 units at $5.49), decreasing direct ownership by 3% to 27,942 units (SEC Form 4) to satisfy withholding obligation
- Chief Medical Officer Deykin Aaron sold $4,914 worth of shares (895 units at $5.49), decreasing direct ownership by 3% to 32,302 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Houghton Adam sold $3,843 worth of shares (700 units at $5.49), decreasing direct ownership by 3% to 22,901 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Sutherland Everett Rand sold $11,502 worth of shares (2,095 units at $5.49), decreasing direct ownership by 3% to 68,717 units (SEC Form 4) (withholding obligation)
- Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
- Upstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
- Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.
- SEC Form 10-Q filed by Upstream Bio Inc.